9 results match your criteria: "Madison (N.A.C.); and Brown University and Butler Hospital[Affiliation]"
Alzheimer's Disease, Biomarkers, and mAbs - What Does Primary Care Need?
N Engl J Med
June 2024
From the Department of Medicine, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health, Madison (N.A.C.); and the Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia (C.M.E.).
Introduction: Recruitment and retention pose a significant challenge to Alzheimer's disease (AD) research. Returning AD biomarker results to participants has been proposed as a means to improve recruitment and retention. We present findings related to participant satisfaction, utility, and impact on research attitudes from the amyloid positron emission tomography (PET) disclosure sub-study within the Wisconsin Registry for Alzheimer's Prevention (WRAP).
View Article and Find Full Text PDFLongitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD-risk-enriched cohorts.
Alzheimers Dement
May 2024
Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Article Synopsis
- Published norms typically miss early cognitive changes linked to dementia, prompting the development of new standards using data from two Alzheimer's risk cohorts.
- The research utilized quantitative regression to create both cross-sectional and longitudinal normative standards based on data from nearly 1,400 cognitively healthy participants over an average of 9 years.
- Findings indicate that lower percentile scores correlate with cognitive impairment and higher Alzheimer’s biomarker levels, while a ShinyApp was created to help visualize scores and identify low performance.
Alzheimer's Disease - Managing Stages of Dementia.
N Engl J Med
March 2024
From the University of Wisconsin School of Medicine, Madison (N.A.C.); and Brown University and Butler Hospital, Providence, RI (S.S.).
Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and Screening.
N Engl J Med
March 2024
From University of Wisconsin Medicine, Madison (N.A.C.); and Brown University and Butler Hospital, Providence, RI (S.S.).
An accurate blood test for Alzheimer's disease that is sensitive to preclinical proteinopathy and cognitive decline has clear implications for early detection and secondary prevention. We assessed the performance of plasma phosphorylated tau 217 ( ) against brain PET markers of amyloid [ -labelled Pittsburgh compound B (PiB)] and tau ( MK-6240) and its utility for predicting longitudinal cognition. Samples were analysed from a subset of participants with up to 8 years follow-up in the Wisconsin Registry for Alzheimer's Prevention (WRAP; 2001-present; plasma 2011-present), a longitudinal cohort study of adults from midlife, enriched for parental history of Alzheimer's disease.
View Article and Find Full Text PDFIncidental Findings from 16,400 Brain MRI Examinations of Research Volunteers.
AJNR Am J Neuroradiol
April 2023
From the University of Wisconsin School of Medicine and Public Health (P.A.R., L.B.E., A.S.F., R.J.D., S.C.J., S.A., V.P., B.B.B., B.R.P., H.H.G., C.M.C., M.A.B., N.H.K., L.E.W., H.A.R.).
Background And Purpose: Incidental findings are discovered in neuroimaging research, ranging from trivial to life-threatening. We describe the prevalence and characteristics of incidental findings from 16,400 research brain MRIs, comparing spontaneous detection by nonradiology scanning staff versus formal neuroradiologist interpretation.
Materials And Methods: We prospectively collected 16,400 brain MRIs (7782 males, 8618 females; younger than 1 to 94 years of age; median age, 38 years) under an institutional review board directive intended to identify clinically relevant incidental findings.
Schwartz-Matsuo syndrome: An important cause of secondary glaucoma.
Am J Ophthalmol Case Rep
March 2020
Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Purpose: We report a case of Schwartz-Matsuo syndrome that highlights the pathophysiology, diagnostic challenges, and management considerations of this rare disease.
Observations: 31-year-old man with a history of left eye cataract presented with left eye photophobia and elevated intraocular pressure (IOP) of 64 mm Hg. Visual acuity 20/40.
Glucocorticoid receptor-like Zn(Cys)4 motifs in BslI restriction endonuclease.
J Mol Biol
November 2003
Structural Biology Program, Department of Physiology and Biophysics, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA.
BslI restriction endonuclease cleaves the symmetric sequence CCN(7)GG (where N=A, C, G or T). The enzyme is composed of two subunits, alpha and beta, that form a heterotetramer (alpha(2)beta(2)) in solution. The alpha subunit is believed to be responsible for DNA recognition, while the beta subunit is thought to mediate cleavage.
View Article and Find Full Text PDF